fashion -WSS

fashion

author：knowledge 2025-09-06 03:53:34 - browse：66894

Rod Nathan, Ali Urman, and Patrick Nosker on the 2024 Breakthrough Summit East stage. — From left, Rod Nathan, portfolio manager and partner of J. Goldman & Co.; ARK Invest senior analyst Ali Urman; and Patrick Nosker, director of research and partner at Affinity Asset Advisors, discuss biotech investment opportunities at the 2024 STAT Breakthrough Summit East. STAT

Following a blockbuster year of dealmaking and a recent uptick in biotech stocks, top investors see more good news on the horizon.

Driving the momentum? Economics 101.

Biotechs rely on borrowing capital, which is a more tenuous task when interest rates are high. But interest rates have most likely peaked, with Federal Reserve officials signaling earlier this week they expected to make three cuts this year. For public biotechnology startups that have been battered by the market in recent years, this is a very good thing, Rod Nathan, portfolio manager and partner of J. Goldman & Co., said on a panel at STAT’s Breakthrough Summit East in New York on Thursday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Clinicians often fail to acknowledge the pain caused by long Covid

Wikipedia

WSS

Clinicians often fail to acknowledge the pain caused by long Covid

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Congress: Prevent baby formula shortages by passing a new bill

The Bio Revolution is changing business and society

STAT Summit: How researchers deal with rejection

entertainment

fashion

knowledge

Bright Health sells Medicare Advantage business to Molina

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Psychedelics group wrestles with new pharma identity

Results on Novartis prostate cancer therapy could expand its use

Novavax promises a turnaround & Lilly roils the obesity market

STAT Summit: Meghan O’Rourke on making chronic illness visible

Supreme Court strikes down use of affirmative action

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Alkermes shareholders re

Roivant's CEO is a star, but biotech's black hole persists

explore

STAT Summit: The economic case for universal basic health care

How AI can help patients find reliable information about doctors

Decentralized clinical trials need collaboration to achieve wider use

Questions loom on AstraZeneca cancer drug as safety concerns ebb

ADCs take center stage as promising cancer treatments

Health tech investors get more selective as pandemic boom fades

Wikipedia

hotspot

leisure time

focus